Neil J Scolding

List of Publications by Year
in descending order

132 papers	5,562 citations	70961 41 h-index	85405 71 g-index
134 all docs	134 docs citations	134 times ranked	5900 citing authors

#	Article	IF	Citations
1	Reduced expression of mitochondrial fumarate hydratase in progressive multiple sclerosis contributes to impaired in vitro mesenchymal stromal cell-mediated neuroprotection. Multiple Sclerosis Journal, 2022, 28, 1179-1188.	1.4	3
2	Amyloid cerebrovasculopathies. Practical Neurology, 2022, , practneurol-2022-003386.	0.5	0
3	Repeat infusion of autologous bone marrow cells in progressive multiple sclerosis â€“ A phase I extension study (SIAMMS II). Multiple Sclerosis and Related Disorders, 2022, 61, 103782.	0.9	0
4	The neurology of chronic nodding syndrome. Brain Communications, 2022, 4, .	1.5	2
5	Alemtuzumab and Fatal Myocarditis. Neurology: Clinical Practice, 2021, 11, e46-e47.	0.8	2
6	Tetanus in a rural low-income intensive care unit setting. Brain Communications, 2021, 3, fcab013.	1.5	7
7	Response to: â€˜Nodding syndrome, many questions remain but we can prevent it by eliminating onchocerciasisâ€™. Brain Communications, 2021, 3, fcaa229.	1.5	3
8	Prolonged disorders of consciousness: a critical evaluation of the new UK guidelines. Brain, 2021, 144, 1655-1660.	3.7	22
9	CNS involvement in systemic vasculitides. Journal of the Neurological Sciences, 2021, 424, 117423.	0.3	4
10	OPTIMISE: MS study protocol: a pragmatic, prospective observational study to address the need for, and challenges with, real world pharmacovigilance in multiple sclerosis. BMJ Open, 2021, 11, e050176.	0.8	3
11	The diagnosis of primary central nervous system vasculitis. Practical Neurology, 2020, 20, 109-114.	0.5	43
12	Factors affecting mortality after traumatic brain injury in a resource-poor setting. BJS Open, 2020, 4, 320-325.	0.7	25
13	Brain biopsy before or after treatment with corticosteroids?. Neuroradiology, 2020, 62, 545-546.	1.1	2
14	Maternal micro-chimeric cells in the multiple sclerosis brain. Multiple Sclerosis and Related Disorders, 2020, 40, 101925.	0.9	2
15	Nodding syndrome: a concise review. Brain Communications, 2020, 2, fcaa037.	1.5	16
16	Neurology and what?. Brain, 2020, 143, 1613-1615.	3.7	1
17	Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. JAMA - Journal of the American Medical Association, 2019, 321, 175.	3.8	336
18	Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance. Neurology, 2018, 90, 819-820.	1.5	15

#	Article	IF	Citations
19	Future Therapies for Progressive Multiple Sclerosis. , 2018, , 275-300.		0
20	Bone marrow transplantation stimulates neural repair in Friedreich's ataxia mice. Annals of Neurology, 2018, 83, 779-793.	2.8	14
21	Aberrant cerebellar Purkinje cell function repaired in vivo by fusion with infiltrating bone marrow-derived cells. Acta Neuropathologica, 2018, 135, 907-921.	3.9	16
22	Reduced cellularity of bone marrow in multiple sclerosis with decreased MSC expansion potential and premature ageing in vitro. Multiple Sclerosis Journal, 2018, 24, 919-931.	1.4	35
23	Reduced neuroprotective potential of the mesenchymal stromal cell secretome with ex vivo expansion, age and progressive multiple sclerosis. Cytotherapy, 2018, 20, 21-28.	0.3	27
24	Advising patients seeking stem cell interventions for multiple sclerosis. Practical Neurology, 2018, 18, 472-476.	0.5	7
25	Dysregulation of Mesenchymal Stromal Cell Antioxidant Responses in Progressive Multiple Sclerosis. Stem Cells Translational Medicine, 2018, 7, 748-758.	1.6	27
26	Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, The, 2017, 16, 271-281.	4.9	134
27	Can the optic nerve be repaired?. Lancet Neurology, The, 2017, 16, 172-173.	4.9	0
28	Cell Therapy for Multiple Sclerosis. CNS Drugs, 2017, 31, 453-469.	2.7	19
29	Mesenchymal Stem Cell-Derived Factors Restore Function to Human Frataxin-Deficient Cells. Cerebellum, 2017, 16, 840-851.	1.4	8
30	Overexpression of Kinesin Superfamily Motor Proteins in Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 60, 1511-1524.	1.2	29
31	Neurosarcoidosis: a clinical approach to diagnosis and management. Journal of Neurology, 2017, 264, 1023-1028.	1.8	81
32	Cell-based therapeutic strategies for multiple sclerosis. Brain, 2017, 140, 2776-2796.	3.7	139
33	Percutaneous Endoscopic Gastrostomy Tube Insertion in Neurodegenerative Disease: A Retrospective Study and Literature Review. Clinical Endoscopy, 2017, 50, 270-278.	0.6	39
34	Purkinje cell injury, structural plasticity and fusion in patients with Friedreichâ€™s ataxia. Acta Neuropathologica Communications, 2016, 4, 53.	2.4	36
35	Ovarioleukodystrophy due toEIF2B5mutations. Practical Neurology, 2016, 16, 496-499.	0.5	9
36	Oxidative stress-related biomarkers in multiple sclerosis: a review. Biomarkers in Medicine, 2016, 10, 889-902.	0.6	49

#	Article	IF	Citations
37	Intracranial spread of IgG4-related disease via skull base foramina. Practical Neurology, 2016, 16, 240-242.	0.5	13
38	Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort. Multiple Sclerosis Journal, 2016, 22, 1215-1223.	1.4	85
39	Erdheim-Chester disease: 25-year history with early CNS involvement. BMJ Case Reports, 2016, 2016, bcr2016216747.	0.2	3
40	Stem Cells for Multiple Sclerosis. , 2016, , 259-273.		0
41	Assessment of bone marrow-derived Cellular Therapy in progressive Multiple Sclerosis (ACTiMuS): study protocol for a randomised controlled trial. Trials, 2015, 16, 463.	0.7	37
42	Repeat infusion of autologous bone marrow cells in multiple sclerosis: protocol for a phase I extension study (SIAMMS-II). BMJ Open, 2015, 5, e009090.	0.8	14
43	PATIENT-REPORTED OUTCOMES AND DISABILITY IN MULTIPLE SCLEROSIS. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.32-e4.	0.9	0
44	Reductions in kinesin expression are associated with nitric oxideâ€induced axonal damage. Journal of Neuroscience Research, 2015, 93, 882-892.	1.3	23
45	Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Practical Neurology, 2015, 15, 273-279.	0.5	169
46	Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, e93.	3.1	70
47	The best clinical paper on multiple sclerosis in 2014. Multiple Sclerosis Journal, 2015, 21, 854-855.	1.4	0
48	Idiopathic hypereosinophilic syndrome: a new cause of vasculitis of the central nervous system. Journal of Neurology, 2015, 262, 1354-1359.	1.8	13
49	Tumefactive demyelination presenting during bevacizumab treatment. BMJ Case Reports, 2015, 2015, bcr2015212173.	0.2	5
50	CD34+ STEM CELL MOBILISATION IN MS TREATMENT AND RELAPSE. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.61-e4.	0.9	0
51	Increased microglial catalase activity in multiple sclerosis grey matter. Brain Research, 2014, 1559, 55-64.	1.1	18
52	Immune reconstitution and treatment response in multiple sclerosis following alemtuzumab. Neurology, 2014, 82, 2150-2151.	1.5	7
53	Acute disseminated encephalomyelitis and other inflammatory demyelinating variants. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2014, 122, 601-611.	1.0	13
54	Cell therapy for multiple sclerosis: an evolving concept with implications for other neurodegenerative diseases. Lancet, The, 2013, 382, 1204-1213.	6.3	54

#	Article	IF	Citations
55	Primary progressive multiple sclerosis: progress and challenges. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 1100-1106.	0.9	56
56	Future Therapies for Progressive Multiple Sclerosis. , 2013, , 221-243.		1
57	We are about to cure multiple sclerosis in the next 10 years, even though we do not know its cause: Yes. Multiple Sclerosis Journal, 2012, 18, 782-783.	1.4	0
58	Purkinje cell fusion and binucleate heterokaryon formation in multiple sclerosis cerebellum. Brain, 2012, 135, 2962-2972.	3.7	38
59	Human bone marrow mesenchymal stem cells protect catecholaminergic and serotonergic neuronal perikarya and transporter function from oxidative stress by the secretion of glial-derived neurotrophic factor. Brain Research, 2012, 1431, 86-96.	1.1	50
60	Brain biopsy in cryptogenic neurological disease. British Journal of Neurosurgery, 2011, 25, 614-620.	0.4	23
61	Mechanisms of Oxidative Damage in Multiple Sclerosis and a Cell Therapy Approach to Treatment. Autoimmune Diseases, 2011, 2011, 1-11.	2.7	80
62	The other BSE. Brain, 2011, 134, 2194-2196.	3.7	2
63	Mesenchymal Stem Cells Restore Frataxin Expression and Increase Hydrogen Peroxide Scavenging Enzymes in Friedreich Ataxia Fibroblasts. PLoS ONE, 2011, 6, e26098.	1.1	24
64	Human Mesenchymal Stem Cells Infiltrate the Spinal Cord, Reduce Demyelination, and Localize to White Matter Lesions in Experimental Autoimmune Encephalomyelitis. Journal of Neuropathology and Experimental Neurology, 2010, 69, 1087-1095.	0.9	85
65	Cerebral amyloid angiopathy related vasculitis: successful treatment with azathioprine. Journal of Neurology, 2010, 257, 2103-2105.	1.8	16
66	Mesenchymal stem cellâ€secreted superoxide dismutase promotes cerebellar neuronal survival. Journal of Neurochemistry, 2010, 114, 1569-1580.	2.1	107
67	Multipotent adult progenitor cell isolation and proliferation in cytokine and serumâ€free medium conditioned by rat B104 cells. British Journal of Haematology, 2010, 148, 441-444.	1.2	8
68	Safety and Feasibility of Autologous Bone Marrow Cellular Therapy in Relapsing-Progressive Multiple Sclerosis. Clinical Pharmacology and Therapeutics, 2010, 87, 679-685.	2.3	75
69	PAF66 Brain biopsy in neurological disease. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e17-e17.	0.9	0
70	Stem cells in genetic myelin disorders. Regenerative Medicine, 2010, 5, 425-439.	0.8	8
71	Neurolupus. Practical Neurology, 2010, 10, 4-15.	0.5	59
72	The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Multiple Sclerosis Journal, 2010, 16, 503-510.	1.4	212

#	Article	IF	Citations
73	Characterization of in vitro expanded bone marrow-derived mesenchymal stem cells from patients with multiple sclerosis. Multiple Sclerosis Journal, 2010, 16, 909-918.	1.4	62
74	Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Research, 2009, 3, 63-70.	0.3	253
75	Central nervous system vasculitis. Seminars in Immunopathology, 2009, 31, 527-536.	2.8	45
76	Mesenchymal Stem Cells and Neurodegenerative Disease. Clinical Pharmacology and Therapeutics, 2009, 85, 19-20.	2.3	10
77	Human Mesenchymal Stem Cell Culture for Neural Transplantation. Methods in Molecular Biology, 2009, 549, 103-118.	0.4	12
78	Neural cell transplantation: methods and protocols. Preface. Methods in Molecular Biology, 2009, 549, v.	0.4	0
79	Chapter 44 Vasculitis and stroke. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 93, 873-886.	1.0	2
80	Enhanced green fluorescent protein-expressing human mesenchymal stem cells retain neural marker expression. Journal of Neuroimmunology, 2008, 193, 59-67.	1.1	14
81	Autologous bone marrow stem cells â€" properties and advantages. Journal of the Neurological Sciences, 2008, 265, 59-62.	0.3	32
82	Autologous mesenchymal bone marrow stem cells: Practical considerations. Journal of the Neurological Sciences, 2008, 265, 111-115.	0.3	23
83	Human mesenchymal stem cells abrogate experimental allergic encephalomyelitis after intraperitoneal injection, and with sparse CNS infiltration. Neuroscience Letters, 2008, 448, 71-73.	1.0	116
84	Disease-responsive neural precursor cells are present in multiple sclerosis lesions. Regenerative Medicine, 2008, 3, 835-847.	0.8	36
85	Can diffusion-weighted imaging improve the diagnosis of CNS vasculitis?. Nature Clinical Practice Neurology, 2007, 3, 608-609.	2.7	8
86	Strategies for achieving and monitoring myelin repair. Journal of Neurology, 2007, 254, 275-283.	1.8	5
87	AÂ-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain, 2005, 128, 500-515.	3.7	329
88	Stem-cell therapy: hope and hype. Lancet, The, 2005, 365, 2073-2075.	6.3	18
89	Devic's disease and autoantibodies. Lancet Neurology, The, 2005, 4, 136-7.	4.9	11
90	Cell therapy in demyelinating diseases. NeuroRx, 2004, 1, 415-423.	6.0	11

#	Article	IF	Citations
91	Adult stem cellsâ€"reprogramming neurological repair?. Lancet, The, 2004, 364, 193-199.	6.3	70
92	Subacute neurological syndromes. Clinical Medicine, 2004, 4, 122-124.	0.8	1
93	Cell therapy in demyelinating diseases. Neurotherapeutics, 2004, 1, 415-423.	2.1	0
94	First attack in multiple sclerosis: harbinger or history?. Lancet Neurology, The, 2003, 2, 526.	4.9	0
95	Stem cells for the treatment of neurological disease. Transfusion Medicine, 2003, 13, 351-361.	0.5	22
96	Cerebral Vasculitis: A Practical Approach. Practical Neurology, 2002, 2, 80-93.	0.5	39
97	New Cells, New Brain. Practical Neurology, 2002, 2, 128-129.	0.5	0
98	A Young Man with a Fatal Encephalopathy. Practical Neurology, 2002, 2, 26-35.	0.5	1
99	Cell transplantation, myelin repair, and multiple sclerosis. Lancet Neurology, The, 2002, 1, 31-40.	4.9	48
100	The recognition, diagnosis and management of cerebral vasculitis: a European survey. European Journal of Neurology, 2002, 9, 343-347.	1.7	45
101	The neuropathology and pathogenesis of systemic lupus erythematosus. Neuropathology and Applied Neurobiology, 2002, 28, 173-189.	1.8	83
102	New cells from old. Lancet, The, 2001, 357, 329-330.	6.3	19
103	Use of stem cells in creation of embryos. Lancet, The, 2001, 358, 2078.	6.3	0
104	Glial cells as targets for cytotoxic immune mediators. Glia, 2001, 36, 200-211.	2.5	38
105	Remyelination of Demyelinated CNS Axons by Transplanted Human Schwann Cells: The Deleterious Effect of Contaminating Fibroblasts. Cell Transplantation, 2001, 10, 305-315.	1.2	38
106	Remyelination of demyelinated CNS axons by transplanted human schwann cells: the deleterious effect of contaminating fibroblasts. Cell Transplantation, 2001, 10, 305-15.	1.2	10
107	CENTRAL NERVOUS SYSTEM ANGIITIS.. Brain, 2000, 123, 2364-2365.	3.7	0
108	Oligodendroglia are protected from antibody-mediated complement injury by normal immunoglobulins (â€œIVIgâ€). Journal of Neuroimmunology, 2000, 103, 195-201.	1.1	47

#	Article	IF	Citations
109	Mechanisms of damage to myelin and oligodendrocytes and their relevance to disease. Neuropathology and Applied Neurobiology, 1999, 25, 435-458.	1.8	96
110	Paraneoplastic sensory neuropathy and Purkinje cell antibodies. Muscle and Nerve, 1999, 22, 1466-1467.	1.0	2
111	Identification of A2B5-positive putative oligodendrocyte progenitor cells and A2B5-positive astrocytes in adult human white matter. Neuroscience, 1999, 89, 1-4.	1.1	86
112	The expression of complement regulatory proteins by adult human oligodendrocytes. Journal of Neuroimmunology, 1998, 84, 69-75.	1.1	62
113	Axon loss in multiple sclerosis. Lancet, The, 1998, 352, 340-341.	6.3	68
114	Cerebral vasculitis--recognition, diagnosis and management. QJM - Monthly Journal of the Association of Physicians, 1997, 90, 61-73.	0.2	58
115	Review: Glial lineages and myelination in the central nervous system. Journal of Anatomy, 1997, 190, 161-200.	0.9	96
116	Remyelination in demyelinating disease. BailliÃ¨re's Clinical Neurology, 1997, 6, 525-48.	0.2	5
117	A proliferative adult human oligodendrocyte progenitor. NeuroReport, 1995, 6, 441-445.	0.6	113
118	Grovith factors fail to protect rat oligodendrocytes against humoral injury in vitro. Neuroscience Letters, 1995, 183, 75-78.	1.0	11
119	The pathogenesis of demyelinating disease. Progress in Neurobiology, 1994, 43, 143-173.	2.8	53
120	INTERACTIONS BETWEEN OLIGODENDROCYTES AND MICROGLIA. Brain, 1992, 115, 1611-1631.	3.7	138
121	INTERACTIONS BETWEEN OLIGODENDROCYTES AND MICROGLIA. Brain, 1992, 115, 1611-1631.	3.7	126
122	The role of calcium in rat oligodendrocyte injury and repair. Neuroscience Letters, 1992, 135, 95-98.	1.0	34
123	Oligodendrocyte-macrophage interactions in vitro triggered by specific antibodies. Immunology, 1991, 72, 127-32.	2.0	32
124	Complement mediated serum cytotoxicity against oligodendrocytes: a comparison with other cells of the oligodendrocyte-type 2 astrocyte lineage. Journal of the Neurological Sciences, 1990, 97, 155-162.	0.3	22
125	Oligodendrocyte susceptibility to injury by T-cell perforin. Immunology, 1990, 70, 6-10.	2.0	52
126	Immune Mechanisms in the Pathogenesis of Demyelinating Diseases. Autoimmunity, 1989, 4, 131-142.	1.2	21

#	Article	IF	Citations
127	Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature, 1989, 339, 620-622.	13.7	237
128	Myelin-oligodendrocyte glycoprotein (MOG) is a surface marker of oligodendrocyte maturation. Journal of Neuroimmunology, 1989, 22, 169-176.	1.1	119
129	Normal rat serum cytotoxicity against syngeneic oligodendrocytes. Journal of the Neurological Sciences, 1989, 89, 289-300.	0.3	113
130	Reversible injury of cultured rat oligodendrocytes by complement. Immunology, 1989, 67, 441-6.	2.0	42
131	Cerebral Vasculitis. , 0, , 510-515.		0
132	Review: Glial lineages and myelination in the central nervous system. , 0, .		2